Efavirenz plus Lamivudine/Zidovudine — Competitive Intelligence Brief

Efavirenz plus Lamivudine/Zidovudine (Efavirenz plus Lamivudine/Zidovudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NNRTI + NRTIs). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination therapy (NNRTI + NRTIs) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Efavirenz plus Lamivudine/Zidovudine (Efavirenz plus Lamivudine/Zidovudine) — University of Cologne. This combination inhibits HIV reverse transcriptase through three complementary mechanisms: efavirenz as a non-nucleoside reverse transcriptase inhibitor and lamivudine/zidovudine as nucleoside reverse transcriptase inhibitors.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Efavirenz plus Lamivudine/Zidovudine TARGET	Efavirenz plus Lamivudine/Zidovudine	University of Cologne	phase 3	Antiretroviral combination therapy (NNRTI + NRTIs)	HIV reverse transcriptase
Tenofovir disoproxil/emtricitabine/rilpivirine	Tenofovir disoproxil/emtricitabine/rilpivirine	Sheba Medical Center	marketed	Antiretroviral combination (NRTI + NNRTI)	HIV reverse transcriptase
TAF/FTC FDC	TAF/FTC FDC	Janssen Scientific Affairs, LLC	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Tenofovir, Emtricitabine, Raltegravir	Tenofovir, Emtricitabine, Raltegravir	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI/NtRTI + INSTI)	HIV reverse transcriptase and HIV integrase
Tenofovir, lamivudine and efavirenz	Tenofovir, lamivudine and efavirenz	Centre for the AIDS Programme of Research in South Africa	marketed	Antiretroviral combination therapy (NRTI/NtRTI + NNRTI)	HIV reverse transcriptase, HIV integrase
tenofovir + abacavir + efavirenz	tenofovir + abacavir + efavirenz	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
TAF with a boosted protease inhibitor	TAF with a boosted protease inhibitor	University of Colorado, Denver	marketed	Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor)	HIV reverse transcriptase and HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NNRTI + NRTIs) class)

1. Institut de Recherche pour le Developpement · 1 drug in this class
2. Juan A. Arnaiz · 1 drug in this class
3. University of Cologne · 1 drug in this class